{
  "ticker": "MEM",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02974474",
  "id": "02974474",
  "pages": 9,
  "price_sensitive": true,
  "date": "20250730",
  "time": "1102",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250730/pdf/06m9rsrly1yvg9.pdf",
  "summary": "### **Memphasys Limited \u2013 June 2025 Quarterly Report (Appendix 4C) \u2013 Key Highlights**  \n\n#### **Operational/Financial Highlights**:  \n- **CE Mark submission** for Felix\u2122 completed; approval expected in **6\u201312 months** (potential access to **~$5B European IVF market**).  \n- **Commercial pivot**: Direct sales initiated in **Japan, New Zealand, UAE, and Canada**; **repeat sales in Japan**.  \n- **RoXsta\u2122 Mega Cell assay** validated (96 samples/hour) for fertility, livestock, and sports diagnostics.  \n- **Capital raising**: **$1.275M** placement completed ($0.006/share + attaching options).  \n- **Cash balance**: **$298k** at quarter-end (vs. $287k prior quarter). **0.23 quarters of funding remaining**\u2014further capital raising planned.  \n\n#### **Liquidity/Capital Structure**:  \n- **Financing facilities**: **$4.52M drawn** (of $4.77M total), including:  \n  - **Convertible note**: $3M + fees (8% coupon, matures Dec 2025).  \n  - **R&D loan**: $638k (15% coupon, matures Nov 2025).  \n- **Cash burn**: **$1.32M net operating outflow** (quarter); reliant on near-term fundraising.  \n\n#### **Board Changes**:  \n- **Appointment**: Marjan Mikel (medtech/commercialisation expertise).  \n- **Resignation**: Michael Atkins (NED, due to time constraints).  \n\n---  \n**Omitted**: Routine operational details, director bios, forward-looking qualifiers.",
  "usage": {
    "prompt_tokens": 5010,
    "completion_tokens": 355,
    "total_tokens": 5365,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-30T01:46:44.393297"
}